THE EFFECT OF NON-STEROIDAL ANTI-INFLAMMATORY THERAPY IN THE CORRECTION OF THE COGNITIVE IMPAIRMENT FOR PATIENTS WITH CHRONIC CEREBRAL ISCHEMIA AND METABOLIC SYNDROME

PUMTS. 2019; 36(4): 42-48.
https://doi.org/10.31071/promedosvity2019.04.042

Full text (PDF)

The purpose of the research was to study the effectiveness of the use of non-steroidal anti-inflammatory drugs (NSAIDs) for the correction of the cognitive impairment (CI) for patients with chronic cerebral ischemia (CCI) and metabolic syndrome (MS).
The study involved 118 patients with CCI, divided in 2 groups: with and without MS. Each group was divided into 2 subgroups depending on the type of treatment: with the addition of NSAIDs to the basic therapy or not. The degree of cognitive impairment was determined according to the scales MoCA, FAB, Schulte tables. We determined serum concentrations of interleukin-6 (IL-6), interleukin-10 (IL-10), vasculoendothelial growth factor (VEGF) by enzyme immunoassay.
It was found that MS did not significantly affect the level of cognitive impairment for patients with CCI before treatment, because it did not significantly differ when compared with patients with CCI without MS (according to the scales MoCA, FAB, Schulte tables). The addition of NSAIDs to the basic therapy for patients with CCI and MS led to a significant improvement in cognitive functions on all scales, while only the basic therapy had a little positive effect only on the test results with Schulte tables. For the patients with CCI without MS, the improvement in cognitive function did not depend on the addition of NSAIDs to the basic therapy. The concentration of VEGF in the blood serum of patients with CCI and MS significantly decreased in the subgroup of patients where NSAIDs were used in treatment, while in the group of patients with CCI without MS there was no reliable dynamics of the concentration of this biomarker as a result of treatment. The effect of basic therapy and basic therapy with the addition of NSAIDs on the serum level of the studied interleukins (IL-6 and IL-10) was not revealed for patients with CCI with or without MS.

REFERENCES
  1. Crichton G. E., Elias M. F., Buckley J. D., Murphy K. J., Bryan J., Frisardi V. (2012). Metabolic Syndrome, сognitive performance and dementia. Journal of Alzheimer’s Disease. Vol. 30(2). (pp. 77-87). DOI: 10.3233/JAD-2011-111022.
  2. Darii V. I. (2019). Hronіchna nedostatnіst’ mozkovogo krovoobіgu [Chronic insufficiency of cerebral blood circulation]. Navchalnij posibnik dlya likariv interniv-nevrologiv ta nevrologiv – Tutorial for physicians interns-neurologists and neurologists. Zaporizhzhia [in Ukrainian].
  3. Pourenko T. Y. (2014). Problema kognіtivnih rozladіv u nevrologіchnіj prakticі [The problem of cognitive disorders in neurological practice]. Bukovins’kij medichnij vіsnik – Bukovyna medical bulletin, 4(72), 216-221 [in Ukrainian].
  4. Mishchenko T. S. (2013). Discirkulyatornaya encefalopatiya: ustarevshij termin ili klinicheskaya real’nost’? [Discirculatory encephalopathy: an outdated term or clinical reality?] Mezhdunarodnyj nevrologicheskij zhurnal «Praktikuyushchemu nevrologu» – International neurological journal “Practicing Neurologist”, 2(56), 134-138 [in Russian].
  5. Farooqui T., Farooqui A. A. (2013). Metabolic syndrome and neurological disorders. Willey-Blackwell, 1 edition. DOI: 10.1007/s00018-011-0840-1.
  6. Mottillo S., Filion K. B., Genest J., Joseph L., Pilote L., Poirier P., Rinfret S., Schiffrin E. L., Eisenberg M. J. (2010). The metabolic and cardiovascular risk. A systematic review and meta-analysis. Journal of the American College of Cardiology. Vol. 56(14). (pp. 1113-1132). DOI: 10.1016/j.jacc.2010.05.034.
  7. Reusch J. B. R., Low Wang C. C. (2011). Cardiovascular disease in diabetes: where does glucose fit in? Journal of Clinical Endocrinology and Metabolism. Vol. 96(8). (pp. 2367-2376). DOI: 10.1210/jc.2010-3011.
  8. Luo L., Yang M., Hao Q., Yue J., Dong B. (2013). Cross-sectional study examining the association between metabolic syndrome and cognitive function among the oldest old. Journal of the American Medical Directors Association. Vol. 14(2). (pp. 105-108). DOI: 10.1016/j.jamda.2012.10.001.
  9. Tripolt N. J. (2013). Short communication: Effect of supplementation with Lactobacillus casei Shirota on insulin sensitivity, β-cell function, and markers of endothelial function and inflammation in subjects with metabolic syndrome – a pilot study. Journal of Dairy Science. Vol. 96(1). (pp. 89-95). DOI: 10.3168/jds.2012-5863.
  10. Kovalenko L. V., Belova E. A., Verizhnikova L. N. (2013). Endotelial’naya disfunkciya i metabolicheskij sindrom [Endothelial dysfunction and metabolic syndrome]. Vestnik SurGU – Bulletin of SurGU, 3(17), 8-13 [in Russian].
  11. Rasin M. S., Lavrenko A. V., Borzykh O. A., Rasin S. M., Kaydashev I. P. (2011). Metabolicheskij sindrom — bolezn’ hronicheskogo nizkointensivnogo sistemnogo vospaleniya [Metabolic syndrome – the disease of chronic low-intensity systemic inflammation]. Ukrainskyi terapevtichnyi zhurnal – Ukrainian therapeutic journal, 4, 56-62 [in Russian].
  12. Kopchak O.O. (2016). Kognіtivnі, psihoemocіjnі ta klіnіchnі osoblivostі pri sudinnіj patologії golovnogo mozku і metabolіchnomu sindromі u osіb rіznogo vіku [Cognitive, psycho-emotional and clinical features in vascular pathology of the brain and metabolic syndrome in persons of different ages]. Avtoreferat disertacії doktora medichnih nauk – Abstract of the dissertation of doctor of medical sciences. Kyiv [in Ukrainian].
  13. Temp F. R., Marafiga J. R., Milanesi L. H., Duarte T., Rambo L. M., Pillat M. M., Mello C. F. (2017). Cyclooxygenase-2 inhibitors differentially attenuate pentylenetetrazol-induced seizures and increase of pro- and anti-inflammatory cytokine levels in the cerebral cortex and hippocampus of mice. European Journal of Pharmacology. Vol. 810. (pp. 15-25). DOI: 10.1016/j.ejphar.2017.05.013.
  14. Russo A., Costagliola C., Delcassi L., Parmeggiani F., Romano M. R., Omo R., Semeraro F. (2013). Topical Nonsteroidal Anti-Inflammatory Drugs for Macular Edema. Journal “Mediators of Inflammation”. Vol. 2013. (pp. 1-11). DOI: 10.1155/2013/476525.
  15. Xu L., Croix B. S. (2014). Improving VEGF-targeted therapies through inhibition of COX-2.PGE2 signaling. Journal ‘Molecular & Cellular Oncology’. Vol. 1(4). (pp. e969154-1 – e969154-3). DOI: 10.4161/23723548.2014.969154.
  16. Mishchenko T. S., Lapshina I. A., Mishchenko V. N. (2010). Hronicheskaya ishemiya mozga (kriterii diagnostiki, novye vozmozhnosti lecheniya) [Chronic cerebral ischemia (diagnostic criteria, new treatment options)]. Ukrainskyi medichnii chasopis – Ukrainian medical chronicle, 6(80), 101-104 [in Russian].
  17. Mitchenko O. I., Karpachov V. V. (2011). Dіagnostika і lіkuvannya metabolіchnogo sindromu, cukrovogo dіabetu, predіabetu і sercevo-sudinnih zahvoryuvan’: rekomendacії asocіacії kardіologіv Ukraїni ta asocіacії endokrinologіv Ukraїni [Diagnostic and prevention of metabolic syndrome, diabetes, prediabetes and cardiovascular diseases: recommendations of the Association of Cardiologists of Ukraine and Association of Endocrinologists of Ukraine]. Sercevo-sudinnі zahvoryuvannya: rekomendacії z dіagnostiki, profіlaktiki ta lіkuvannya – Cardiovascular diseases: diagnostic, prophylaxis and treatment recommendations, 68-79 [in Ukrainian].
Короткая ссылка на эту статью: http://promedosvity.in.ua?lang=en&p=5424

Оставить комментарий

You must be logged in to post a comment.